GlobeNewswire by notified

Money Carer, Tag Systems & Fingerprints Partner on Biometric Payment Card for Vulnerable People in the UK

Share

Money Carer, a UK-based national social enterprise focused on providing secure money management services for vulnerable people, has partnered with global card manufacturer Tag Systems and world-leading biometrics company Fingerprint Cards AB (Fingerprints™). The companies have created and launched a biometric-enabled ‘carer card’, addressing barriers that have traditionally restricted vulnerable people in the UK from accessing financial services.

In 2010, Money Carer invented and launched the first ‘carer card’ – a secure shopping card solution that enables carers to make purchases for those they care for. The card system has since evolved, offering balance limits, a sweep system, free ATM withdrawals, and spending controls. Today, the Money Carer Card supports hundreds of care providers and thousands of individual carers across the UK and is also used by many local authorities and law firms who are responsible for managing the finances of their own vulnerable clients.

Prior to incorporating Fingerprints’ technology, the Money Carer Card relied on the PIN as a means of authentication. Vulnerable cardholders, or their carers, no longer need to remember and enter a PIN to make a payment. They simply place their selected thumb or finger on the sensor and tap to make the payment at the point of sale. This simultaneously simplifies the checkout process while enhancing security.

Sean Tyrer, CEO of Money Carer, comments: “At Money Carer, we are absolutely committed to promoting inclusivity and autonomy. For many of our clients, especially those with memory or visual impairments, the PIN on a payment card is a barrier that restricts financial inclusivity. With biometrics, our clients will never have to remember or input a PIN again, opening doors to financial autonomy that were previously closed.”

The next-generation carer cards come from Tag Systems, which incorporate Fingerprints’ second-generation T-Shape® (T2) sensor module, software platform and algorithm. Tag’s unique Biometric Card as a Service (BCaaS) offering which includes payment processing, allows Money Carer to issue the next generation cards seamlessly.  The cards will be available soon through the Money Carer website and app. For each account with Money Carer, up to five biometrics-enabled cards can be issued.

Adam Philpott, CEO of Fingerprints, comments: “Our primary objective at Fingerprints has always been to make strong authentication simple. We’re extremely proud to be part of a project directly addressing barriers that have traditionally restricted vulnerable people from accessing financial services. This is a perfect example of how technology can be used to drive inclusivity.”

Learn more about how biometric authentication is unlocking the future of card payments here.

About Tag Systems
Tag Systems, was created in Andorra in 1999 and is now part of the Austria Card group of companies.

Tag is a specialist provider of Fintech cards and associated technology.
Tag has two state of the art card manufacturing facilities, and service bureaus in the UK, Poland, Spain and the USA. Tag Systems has expanded its offer with biometric cards, metal cards, Virtual cards and the integration of innovative solutions such as payment processing into their portfolio.

About Fingerprints
Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and seamless universe where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information, visit our website, read our blog, and follow us on Twitter. Fingerprints is listed on Nasdaq Stockholm (FING B).

About Money Carer
Money Carer is the largest provider of appointeeship services for vulnerable adults in the UK. Founded in 2009, the organisation also provides banking and payments services to court of protection deputyship teams for local authorities and law firms via its proprietary banking and payments platform. For more information, visit our website or listen to our podcast.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye